Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ESMO 2018 in depth: Resistance mechanisms to osimertinib in patients with NSCLC and a EGFR T790M mutation

Vassiliki Papadimitrakopoulou, MD, oncologist at the MD Anderson Cancer Centre in Texas, provides information on EGFR mutations associated with resistance to osimertinib in patients with NSCLC and a T790M mutation. These results are from an analysis of the AURA3 study.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items

Congress news 10/10/2019

ESMO 2019 Osimertinib as first-line treatment for NSCLC: final OS analysis

The FLAURA-studie compares the effectivity of the EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib to the EGFR-TKI's gefitinib of erlotinib in NSCLC. In 2018, benefit in progression-free survival was reported for osimertinib. At this ESMO congress, dr. Suresh Ramalingam (Winship Cancer Institute of Emory University), presented the results on overall survival.

Congress news 10/10/2019

ESMO 2019 Veliparib with carboplatin and paclitaxel in HER2-negative breast cancer

At this ESMO congress, medical oncologist Véronique Diéras presented a late breaking abstract on the BROCADE-3 trial. In this trial the effectivity and tolerability of veliparib with chemotherapy was investigated in patients with BRCA-positive HER2-negatieve breast cancer. In this interview, Dr. Diéras summarizes the main findings.

Congress news 08/10/2019

ESMO 2019 Analysis of tumor hyperprogression with nivolumab in RCTs

Pulmonologist prof. Martin Reck from the LungenClinic Großhansdorf in Germany presented results on a relatively new phenomenon: tumor hyperprogression after treatment with immunotherapy. In the CheckMate 451 cohort, the occurence of this phenomenon with nivolumab-treated es-SCLC patients was evaluated.